baber/WOPTO huggingface dataset:
Patent NZ-277065-A (NZ)
Title: Depilation laser process using pulses of selected durations with selected wavelengths
Inventor: CLEMENT ROBERT MARC
IPC: A61B18/20
Filed: 1994-12-07
Abstract: Mammalian hair is depilated using a laser source capable of emitting pulsed radiation, each pulse having a duration of 1 mu s to 1ms, the radiation having a wavelength in the range of 600 to 1500nm. A selected area of a patient's skin is irradiated by the pulsed radiation, the area having a plurality of irradiation zones; the laser source is successively pulsed so as to irradiate successive zones of the treatment area with the radiation, so as to destroy subdermal biological material associated with hair growth.
Patent NZ-277917-A (NZ)
Title: Oral sustained release formulations of opioid analgesics with initial rapid rise in plasma concentration of opioid and at least 24 hour analgesic effect
Inventor: SACKLER RICHARD
IPC: A61K9/54
Filed: 1994-11-22
Abstract: Oral sustained release opioid formulation comprises: an opioid analgesic, a retardant material to cause the opioid analgesic to be released at a rate to provide an analgesic effect after oral admin. to a human patient for 24 hrs, the formulation when administered in humans providing an initially rapid rate of rise in the plasma conc. of the opioid characterised by providing an absorption half-life of 1-8 hrs. in the fastened state. Method for titrating human patients with a sustained release oral opioid formulation comprises: 1) administering to a human patient on a once-a-day basis a unit dose of an oral sustained release formulation comprising a dose of an opioid analgesic and a retardant material as described above, 2) monitoring pharmacokinetic and pharmacodynamic parameters elicited by the formulation in the human patient and determining whether the pharmacokinetic and/or pharmacodynamic  parameters are appropriate to treat the patient on a repeated basis, 3) titrating t he patient by adjusting the dose of the opioid analgesic administered to the patient by administering a unit dose of the sustained release opioid analgesic formulation if it is determined that the pharmacokinetic and/or the pharmacodynamic parameters are not satisfactory or maintaining the dose of the opioid analgesic in the unit dose at a previously administered amt. if the pharmacokinetic and/or pharmacodynamic parameters are deemed appropriate, 4) continuing the step 3 titration by adjusting the dose of the opioid analgesic until appropriate steady state pharmacokinetic and/or pharmacodynamic parameters are achieved in the patient, and 5) continuing the admin. of the dose of the opioid analgesic in the oral sustained release formulation on a once-a-day basis until treatment is terminated.
Patent NZ-281609-A (NZ)
Title: Aqueous polymer dispersion in which the free monomer content is reduced by treatment with a free radical redox initiator system
Inventor: STANGER BERND
IPC: C08F6/00
Filed: 1995-02-20
Abstract: PCT No. PCT/EP95/00607 Sec. 371 Date Feb. 28, 1997 Sec. 102(e) Date Feb. 28, 1997 PCT Filed Feb. 22, 1995 PCT Pub. No. WO95/33775 PCT Pub. Date Dec. 14, 1995Described is a method of producing an aqueous polymer dispersion, the method calling for further polymerization of the dispersion using a radical mechanism redox initiator system including as the reducing agent the addition compound obtained between a lower ketone and hydrogen sulphite.
Patent NZ-302638-A (NZ)
Title: Immunomodulating composition from bile for the treatment of immune system disorders
Inventor: PERCHESON PAUL B
IPC: A61K35/413
Filed: 1996-03-13
Abstract: A composition for use as an immunomodulator comprising small molecular weight components of less than 3000D, and having the following properties: (a) is extracted from bile of animals using an aqueous soluble alcohol; (b) is capable of stimulating monocytes and macrophages in vitro and in vivo; (c) is capable of modulating tumour necrosis factor production; (d) contains no measurable IL-1 alpha , IL-1 beta , TNF, IL-6, IL-8, IL-4, GM-CSF or IFN- gamma ; (e) has an anti-proliferative effect in a malignant mouse hybridoma cell line; (f) shows no cytotoxicity to human peripheral blood mononuclear cells or lymphocytes; and (g) is not an endotoxin. The composition is useful as an immunomodulator, and in the treatment of diseases and conditions having an immunological component, such as cancer or endometriosis.
Patent NZ-309369-A (NZ)
Title: Piperidine and piperazine derivatives, medicaments
Inventor: CARRUTHERS NICHOLAS I
IPC: C07D211/52
Filed: 1996-06-04
Abstract: The invention relates to compounds of the formula R3, and U are as described herein. The compounds of the invention are NK1 or NK2 or NK3 receptor antagonists and as such are useful in the treatment of diseases such as asthma.
Patent NZ-314662-A (NZ)
Title: Matrix tablet for the prolonged release of the sodium salt of tianeptine
Inventor: HUET DE BAROCHEZ BRUNO
IPC: A61K31/554
Filed: 1997-04-23
Abstract: Tablet matrix in which sustained release of sodium tianeptine (I) is controlled using a polymeric cellulose derivative and a calcium salt is new.
Patent NZ-326093-A (NZ)
Title: Dietary fiber delivery system comprising inulin or fructooligosaccharides (FOS)
Inventor: LICARI JEROME J
IPC: A23G3/00
Filed: 1996-12-23
Abstract: The specification describes a delivery system and method for delivering soluble dietary fibers in a chewable tablet form.  The chewable tablet comprises: At least 10% by weight of a water soluble fiber.  The fiber when combined with water to form a 10% by weight solution exhibits a viscosity at 25° of less than 100 centipoise.
Patent NZ-334714-A (NZ)
Title: Liver proteins as agents against autoimmune diseases
Inventor: PANERAI ALBERTO E
IPC: C07K14/47
Filed: 1997-09-17
Abstract: The preparation of medicaments active against autoimmune diseases, of a protein extractable with perchloric acid from mammal liver, wherein the protein has at least 80% homology with the sequence below: Met Ser Glu Asn Ser Glu Glu Pro Val Gly Glu Ala Lys Ala 1                          5                              10 Pro Ala Ala Ile Gly Pro Tyr Ser Gln Ala Val Leu Val Asp 15                          20                              25 Arg Thr Ile Tyr Ile Ser Gly Gln Leu Gly Met Asp Pro Ala        30                         35                             40 Ser Gly Gln Leu Val Pro Gly Gly Val Val Glu Glu Ala Lys               45                            50                             55 Gln Ala Leu Thr Asn Ile Gly Glu Ile Leu Lys Ala Ala Gly                60                           65                            70 Cys Asp Phe Thr Asn Val Val Lys Ala Thr Val Leu Leu Ala                         75                             80 Asp Ile Asn Asp Phe Ser Ala Val Asn Asp Val Tyr Lys Gln      85                              90                              95 Tyr Phe Gln Ser Ser Phe Pro Ala Arg Ala Ala Tyr Gln Val        100                       105                       110 Ala Ala Leu Pro Lys Gly Gly Arg Val Glu Ile Glu Ala Ile             115                           120                        125 Ala Val Gln Gly Pro Leu Thr Thr Ala Ser Val                    130	             135
Patent NZ-337403-A (NZ)
Title: Manufacture of snap lock fastener tape for resealable bags
Inventor: JOHNSON JAMES R
IPC: B31B19/90
Filed: 1999-08-23
Abstract: A fastener tape 40 to be adhered in the top opening of a resealable bag is formed by longitudinally applying a non-sealable barrier layer 50 along the center part of a tape 42 and adhesive surfaces 60, 62 near to the edges of the tape.  The tape is folded at 51 and a snap lock profile 44 is inserted between the edges 52, 54 of the folded tape and heat sealed to the tape.  The adhesive surfaces 60, 62 become adhered to each other to form a peelable barrier seal above the snap lock fastener 44 when the tape is installed in the top of a bag.  The tape is slit longitudinally at the fold 132 and wound on a roller to later be installed in resealable bags with the lip 236 and wall 238 portions being closer to the opening of the bag than the flange portions 52, 54.
Patent NZ-337697-A (NZ)
Title: An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
Inventor: VAN MILLIGEN FLORINE JOHANNA
IPC: C12Q1/37
Filed: 1998-03-11
Abstract: An ex vivo animal or challenge model as a method to identify protective (recombinant) proteins and rapidly measure protective immunity in intestinal segments, directed against parasites and vaccines directed against parasitic infections and vaccines directed against infection with parasites, such as Fasciola hepatica. The vaccines contain protective (recombinant) proteins identified and shown to be protective in studies using the ex vivo model. The protective (recombinant) proteins are derived from newly excysted juveniles (NEJ) of Fasciola hepatica, and the protective (recombinant) protein or fragments thereof have an apparent molecular weight of 32 kD and N-terminal amino acid sequence comprising the sequence XXDVSWPFWDRMYNY.
Patent NZ-502599-A (NZ)
Title: Inhaler, electrohydrodynamic effects used to produce liquid droplets
Inventor: PIRRIE ALASTAIR BRUCE
IPC: A61M15/00
Filed: 1998-08-07
Abstract: A liquid is supplied from a reservoir 30 to a nozzle 40 where the liquid is subjected to an electric field from electrode 41 to produce charged droplets.  A discharge electrode 50 produces ions to at least partially discharge the droplets.  A further electrode 60, placed outwards of the electrode 50 attracts ions produced by the electrode 50 away from nozzle 40 until sufficient space charge is built up to divert the ions towards the charged droplets to enable the ions to discharge the droplets.  The droplets may be droplets of medication being dispensed in an inhaler.
Patent NZ-508115-A (NZ)
Title: Compositions comprising a potentiator such as IL-18, aka interferon-gamma-inducing factor (IGIF), and chemotherapeutic agents
Inventor: JOHNSON RANDALL K
IPC: A61K31/675
Filed: 1999-05-20
Abstract: Described are compositions comprising potentiators, such as IL-18, also known as interferon-ã-inducing factor (IGIF), in combination with a chemotherapeutic agent, processes for making such compositions, the use of such compositions for the prevention and/or treatment of cancer, and the use of such compositions to inhibit the growth of tumours or cancerous cells in mammals.
Patent NZ-511708-A (NZ)
Title: A method for enhancing protective cellular responses to genotoxic stress in skin
Inventor: JACOBSON ELAINE L
IPC: A61K31/445
Filed: 1999-12-01
Abstract: A pharmaceutical composition for a subject in need of elevation of intracellular NAD content, comprising a pro- NAD agent and a pharmaceutically acceptable carrier, wherein the pro-NAD agent is a compound of formula (I), wherein: R1 is hydrogen or a group that can be enzymatically or chemically removed to generate nicotinic acid following administration, and the Pro-NAD agent has a log Po/w range between 5 and 20, and is at a concentration sufficient to elevate intracellular NAD. The composition is used in a cosmetic method of treating or slowing skin deterioration.
Patent NZ-512581-A (NZ)
Title: Polymeric delivery agents comprising a polymer conjugated to a modified amino acid and derivatives thereof
Inventor: MILSTEIN SAM J
IPC: A61K47/48
Filed: 2000-01-07
Abstract: Polymeric delivery agents, delivery agent compounds and compositions comprising them, which are useful in the delivery of active agents, are provided.  Methods of administration and preparation are also provided. The polymeric delivery agent comprises a polymer conjugated to a modified amino acid or derivative thereof via a linkage group selected from the group consisting of-NHC (O) NH-,-C (O) NH-, NHC(O)-, -OOC-, -COO-, -NHC (O) O-, -OC (O) NH-, -CH2NH-, -NHCH2-, -CH2NHC(O)O-, -OC(O)NHCH2-, -CH2NHCOCH2O-, -OCH2C(O)NHCH2-, NHC (O) CHO-,-OCH :, C (O) NH-,-NH-,-O-, and carbon-carbon bond, with the proviso that the polymeric delivery agent is not a polypeptide or polyamino acid.  The modified amino acids may be acylated or sulfonated amino acids, ketones or aldehydes of acylated or sulfonated amino acids, salts thereof, or polyamino acids or polypeptides of any of the foregoing.
Patent NZ-513976-A (NZ)
Title: Anti-p53 antibodies
Inventor: WARD ROBYN LYNNE
IPC: C12Q1/68
Filed: 2000-03-15
Abstract: An isolated and purified peptide, the peptide comprising the complementarity determining region (CDR) of a human antibody. Also disclosed is an antibody or antibody fragment having a binding affinity to a p53 protein, wherein the antibody or fragment thereof comprises such a peptide.
Patent NZ-515005-A (NZ)
Title: Cystine/glycine rich peptides
Inventor: MALLEE LEON FRANCISCUS
IPC: A23L33/18
Filed: 2001-10-24
Abstract: Preparations comprising a mixture of cysteine-rich peptides comprising 7-20 w/w % cysteine, or a mixture of cysteine- and glycine-rich peptides comprising 7-20 w/w % cysteine and glycine.  Methods for the producing the preparations are also included.  The preparations are useful in the treatment of conditions mediated by oxidative damage and for elevations of cellular glutathion levels.
Patent NZ-516464-A (NZ)
Title: Polymeric film structures useful as shrink bags
Inventor: LIND KEITH D
IPC: B32B27/08
Filed: 2000-06-09
Abstract: An oriented multiple layer polymer films structure comprises: (a) a first barrier layer, the barrier layer having two opposing surfaces; (b) a second layer adhered to one of the surfaces of the barrier layer wherein the composition of the second layer comprises a blend of two ethylene vinyl acetate copolymers; (c) a third layer adhered to the other surface of the barrier layer having the same composition as the second layer; (d) a fourth layer adhered to one of the second or third layers wherein the composition of the fourth layer comprises a blend of two ethylene vinyl copolymers and processing additives; (e) a fifth layer adhered to the other of the second or third layer wherein the composition of the fifth layer comprises a blend of linear low density polyethylene and low density polyethylene with the proviso that the melt index for each ethylene vinyl copolymer blend of each layer of the film structure are the same.
Patent NZ-517578-A (NZ)
Title: Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
Inventor: BENNETT BRYDON L
IPC: C07D413/04
Filed: 2000-08-19
Abstract: A compound having structure of formula (I) where it can be used for treating conditions such as, but not exclusively, rheumatoid arthritis, rheumatoid spondylitis, oseoarthritis, gout, asthma, colitis, hepatitis, multiple sclerosis, psoriasis, eczema, dermatitis, atherosclerosis, restenosis following angioplasty, mycocardial infaction, prevent transplant rejection, neurogenerative disorder such as Alzheimer's disease, Parkinson's disease and spinal cord damage.
Patent NZ-519695-A (NZ)
Title: Paediatric nutritional formula comprising xanthan gum to aid tolerance
Inventor: BORSCHEL MARLENE W
IPC: A23L29/10
Filed: 2001-01-16
Abstract: A pediatric formula and methods for providing nutrition to and enhancing tolerance in pediatric patients is described. The formula may be provided in powder, concentrate or ready-to-feed forms. The pediatric formula comprises, based on a 100 kcal basis, about 8 to about 16 grams carbohydrate (preferably about 9.4 to about 12.3 grams), about 3 to about 6 grams lipid (preferably about 4.7 to about 5.6 grams), about 1.8 to about 3.3 grams protein (preferably about 2.4 to about 3.3 grams), and a tolerance improver comprising about 37 to about 370 milligrams (preferably about 74 to about 222 milligrams, more preferably about 111 to about 148 milligrams) xanthan gum. The formula may also be provided in a powder, which comprises, based on 100 grams of powder, about 30 to about 90 grams carbohydrate (preferably about 48 to about 59), about 15 to about 30 grams lipid (preferably 22 to about 28 grams), about 8 to about 17 grams protein (preferably about 11 to about 17), and about 188 to about 1880 milligrams (preferably about 375 to about 1125, more preferably about 375 to about 1125 milligrams) xanthan gum. The formula preferably further comprises vitamins and minerals and may further comprise a stabilizer. The methods comprise administering to a pediatric patient an effective amount of a pediatric formula, as described.
Patent NZ-519883-A (NZ)
Title: Extraction of DNA from microorganisms in dry soil samples thereby identifying the diversity of the organisms present
Inventor: JEANNIN PASCALE
IPC: C12N9/00
Filed: 2000-11-27
Abstract: Described is a method for preparing nucleic acids from an environment sample, more particularly a method for obtaining a library of nucleic acids from a sample. Also described are nucleic acids of nucleic acid libraries obtained by the method and their use in the synthesis of compounds of therapeutic interest. Further described are means used in the method for obtaining the nucleic acids, such as vectors and processes for preparing such vectors or recombinant host cells containing the nucleic acids. Finally, methods for detecting a nucleic acid of interest within a library of nucleic acids resulting from the method is described, in addition to nucleic acids detected by this method and polypeptides encoded by these nucleic acids.
Patent NZ-520036-A (NZ)
Title: Fishing information system with means for inputting acquired data and database for storing historical data
Inventor: SQUIRES VANCE RANDOLPH
IPC: G06Q10/10
Filed: 2000-12-08
Abstract: The fishing system comprises data acquisition and retrieval system (11). Input means are provided for (i) inputting geographical positioning data indicating the geographical position of a point for fishing using GPS (37), (ii) weather data indicating the prevailing weather conditions (39) (iii) fish data characterising the fish located at or obtained at the point; (iv) time data specifying the date, time or season corresponding to the real-time at the point; and (v) water condition data of the prevailing environment at the point (41-45). A database is provided for storing the data input by the input means (35) relative to the geographical position of the point and linking the data to any previous data stored for the particular geographical position of the point. A graphical user interface accesses the linked data of the database and outputs it in an appropriate medium, usually a display that presents an image pane (25), for interpreting by a user of the system. The system is particularly suited to lobster or prawn fishing in the ocean and can be used to predict where to fish. A method for fishing based on the system is also described.
Patent NZ-522080-A (NZ)
Title: Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis
Inventor: MESFIN GEBRE-MARIAM
IPC: A61K31/541
Filed: 2001-04-17
Abstract: Thioamide oxazolidinones are disclosed in the application to be used as medicaments for the treatment of bone resorption and osteoporosis. The medicaments can be administered to mammalian patients in the form of oral, nasal, parenteral, topical, transdermal or rectal medicines.
Patent NZ-524143-A (NZ)
Title: Electrical connector
Inventor: MOESSNER FRANK
IPC: H01R24/58
Filed: 2001-07-26
Abstract: An electrical connector (1) comprising a connector housing (2) and a printed board (3) with two sets of contact elements (7, 8). The first set of contact elements (7) located on the front face of the printed board (3) protrudes into an opening in the connector housing (2). The second set of contact elements (8) located on the rear face of the printed board (3) is configured in the form of insulation displacement contacts (8). The connector (1) also comprises a cable manager (5) which has a continuous opening and which is configured with recessed receiving elements (20) for guides (19), for wires to be contacted to the insulation displacement contacts (8) and the cable manager (5) can be latched to the connector housing (2).
Patent NZ-526044-A (NZ)
Title: Camera and screen to view cows on rotary platform  and bail closing means controllable by operator
Inventor: HOETS WILLEM FREDERIK
IPC: A01J5/003
Filed: 2002-01-21
Abstract: An  operator stationed adjacent to screen 11 can  view cows  (not  shown) adjacent to camera 10 so as to determined if  they have been sufficiently milked, and the operator  is provided  with  means  (not  shown)  to  enable  control  of closing off bails 7 adjacent the cows.
Patent NZ-526263-A (NZ)
Title: A gardening implement with an elongate head forming a curved working surface
Inventor: CHILDS LEIGH MAURICE
Filed: 2003-06-05
Abstract: A gardening implement includes a handle, a head attached to the handle, the head being of elongate form with a longitudinal axis located at substantially right angles to a longitudinal axis of the handle. The elongate head is at least in part of a cross-sectional shape which forms a curved working surface and a flat surface which extends along the length of the elongate head. A cutting edge extends along the length of the elongate head.
Patent NZ-537245-A (NZ)
Title: Method of testing cardiomyocytes derived from human embryonic stem cells formed in embryoid bodies differentiated into all of the major cardiac muscle cell types, including ventricular, atrial, and nodal cells
Inventor: THOMSON JAMES A
IPC: C12N5/08
Filed: 2003-07-25
Abstract: Disclosed is a method for testing an agent for its effect on human cardiac cells comprising the steps of culturing aggregates of approximately 500-800 undifferentiated human pluripotent embryonic stem cell to produce embryoid bodies. Differentiating the embryoid bodies in vitro for 40-95 days to derive atrial, ventricular and nodal cardiomyocte cell types. A single cardiomyocyte is then measured for its transmembrane potential using an electrode then exposed to an agent and observing whether the action potential of the cardiomyocyte changes.
Patent NZ-540001-A (NZ)
Title: Novel interleukin-1 and tumor necrosis factor-alpha modulators syntheses of said modulators and methods of using said modulators
Inventor: PALLADINO MICHAEL
IPC: A61P35/00
Filed: 2000-05-12
Abstract: Disclosed are compounds of formula (I) wherein: R1 and R1' are covalently linked and are each selected from the group consisting of alkyl, substituted alkyl, alkenyl and substituted alkenyl; R2, R2', R9 and R9' are each separately selected from H, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, acyl and aryl; R3-R5, R7, R8 and R11 -R15 and R3'-R5', R7', R8' and R11'-R15' are separately selected from H, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl and aryl; R6 and R6' are independently selected from H, halogen, alkyl, substituted alky, alkenyl and alkynyl; and R10 and R10' are independently selected from H, halogen, CH2, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alcohol and aryl. Also disclosed are compounds of formula (II) wherein the substituents are as described in the specification. Compounds of the type disclosed are novel interleukin-1 and tumour necrosis factor-alpha modulators useful in the treatment of conditions such as tuberculous pleurisy, rheumatoid pleurisy, cancer, cardiovascular disease, skin redness, diabetes, transplant rejection, otitis media (inner ear infection), sinusitis and viral infection.